About FCM

Founded: 1996
Employees: 91
CEO: Disma Mazzola
WebsiteView website: www.friulchem.com

Friulchem S.p.A. engages in the research, development, and production of original and generic pharmaceutical products for human and veterinary use in Italy. It offers generic cosmoceuticals and food supplements; and chewable cubes for animals. The company was founded in 1996 and is based in Milan, Italy.

Recent FCM News & Updates

New Risk • Nov 20

New major risk - Revenue and earnings growth

Earnings have declined by 7.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 7.8% per year over the past 5 years. Market cap is less than US$10m (€4.38m market cap, or US$4.62m).

Recent updates

No updates

Friulchem S.p.A. Stock Price

FCM Share Price Performance

FCM Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Friulchem S.p.A. Key Details

About FCM

Recent FCM News & Updates

Here's Why Friulchem (BIT:FCM) Is Weighed Down By Its Debt Load

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Recent updates

Friulchem S.p.A. Competitors